THE JOURNAL OF
MATERNAL-FETAL 8v NEONATAL MEDICINE
http://informahealthcare.com/jmf ISSN: 1476-7058 (print), 1476-4954 (electronic) J M a te rn F e ta l N e o n a ta l M e d , 2 0 1 4 ; 2 7 (1 2 ): 1 28 9 © 2 0 1 4 In fo rm a UK L td . DOI: 1 0 .3 1 0 9 /1 4 7 6 7 0 5 8 .2 0 1 3 .8 5 4 4 8 0
informa healthcare
LETTER TO THE EDITOR
Author's reply to: Al-Abdi SY. Virus-inactivated plasma and intraven tricular hemorrhage in preterm neonates Gili Kenet1, A. A. Kuperman2, and B. Brenner3 ’ Thrombosis Unit, N ational Hem ophilia Center & Sheba Medical Center, Tel Hashomer, Israel, 2Pediatric Hematology Clinic and Coagulation Service, Western Galilee Hospital, Naharia, Israel; Faculty o f Medicine in the Galilee, Bar-llan University, Safed, Israel, and th ro m b o s is and Hemostasis Unit, Departm ent o f Hematology, Rambam Health Care Campus an d Technion-lsrael Institute o f Technology, Haifa, Israel
We would like to thank Dr Al-Abdi for his interest in our publications addressing the coagulation perspective regarding intraventricular haemorrhage (IVH) in preterm infants [1,2]. We certainly agree with the need to assess the role of specific plasma concentrates applied for the treatment of preterm infants upon potential morbidities. Notably, the two studies [3,4] referred to in our paper - regarding the effect of fresh frozen plasma (FFP) on preventing IVH - did not indicate any specific type of FFP that was used. Due to the heterogeneity of such studies, it is indeed recommended to specify this point in future research. Although one small study [3] reported reduced IVH with volume expansion, this was not supported by any other later study [5,6]. The role of early FFP application after coagulation screening for IVH prevention was reported recently by Dani et al. [4], as discussed in our manuscript. Notably, additional references from the 1990’s [5-8] mentioned by the author might strengthen our conclusions but did not add any new findings, and thus were not quoted within our narrative review. Naturally, as we focused upon hematological interventions, not all other pharmacological agents [9,10] were discussed in detail. In summary, the aim of our publication was to promote the issue of potential IVH prevention by coagulation manipulation. We are happy that this goal has been achieved as increased awareness to the topic is manifested by addressing this rebuttal. We appreciate Dr Al-Abdi’s enligh tening remarks and contribution.
Address for correspondence: Prof. Gili Kenet, Thrombosis unit, National Hemophilia Center & Sheba Medical Center, Tel Hashomer, Israel. E-mail: [email protected]
R eferences 1. Kuperman AA, Brenner B, Kenet G. Intraventricular haemorrhage in preterm infants - can we improve outcome by addressing coagulation? J Matern Fetal Neonatal Med 2013 Aug 23. [Epub ahead of print]. 2. Al-Abdi SY. Virus-inactivated plasma and intraventricular hemor rhage in preterm neonates. J Matern Fetal Neonatal Med 2013; [Epub ahead of print]. 3. Beverley DW, Pitts-Tucker TJ, Congdon PJ, et al. Prevention of intraventricular haemorrhage by fresh frozen plasma. Arch Dis Child 1985;60:710-3. 4. Dani C, Poggi C, Ceciarini F, et al. Coagulopathy screening and early plasma treatment for the prevention of intraventricular hem orrhage in preterm infants. Transfusion 2009;49:2637^44. 5. Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Lancet 1996;348:229-32. 6. The Northern Neonatal Nursing Initiative [NNNI] Trial Group. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. Eur J Pediatr 1996;155:580-8. 7. Ekblad H, Kero P, Shaffer SG, Korvenranta H. Extracellular volume in preterm infants: influence of gestational age and colloids. Early Hum Dev 1991;27:1-7. 8. Ekblad H, Kero P, Korvenranta H. Renal function in preterm infants during the first five days of life: influence of maturation and early colloid treatment. Biol Neonate 1992;61:308-17. 9. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010;(7):CD000174. 10. Cools F, Offringa M. Neuromuscular paralysis for newborn infants receiving mechanical ventilation. Cochrane Database Syst Rev. 2005;(2):CD002773.
Copyright of Journal of Maternal-Fetal & Neonatal Medicine is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
MATERNAL-FETAL 8v NEONATAL MEDICINE
http://informahealthcare.com/jmf ISSN: 1476-7058 (print), 1476-4954 (electronic) J M a te rn F e ta l N e o n a ta l M e d , 2 0 1 4 ; 2 7 (1 2 ): 1 28 9 © 2 0 1 4 In fo rm a UK L td . DOI: 1 0 .3 1 0 9 /1 4 7 6 7 0 5 8 .2 0 1 3 .8 5 4 4 8 0
informa healthcare
LETTER TO THE EDITOR
Author's reply to: Al-Abdi SY. Virus-inactivated plasma and intraven tricular hemorrhage in preterm neonates Gili Kenet1, A. A. Kuperman2, and B. Brenner3 ’ Thrombosis Unit, N ational Hem ophilia Center & Sheba Medical Center, Tel Hashomer, Israel, 2Pediatric Hematology Clinic and Coagulation Service, Western Galilee Hospital, Naharia, Israel; Faculty o f Medicine in the Galilee, Bar-llan University, Safed, Israel, and th ro m b o s is and Hemostasis Unit, Departm ent o f Hematology, Rambam Health Care Campus an d Technion-lsrael Institute o f Technology, Haifa, Israel
We would like to thank Dr Al-Abdi for his interest in our publications addressing the coagulation perspective regarding intraventricular haemorrhage (IVH) in preterm infants [1,2]. We certainly agree with the need to assess the role of specific plasma concentrates applied for the treatment of preterm infants upon potential morbidities. Notably, the two studies [3,4] referred to in our paper - regarding the effect of fresh frozen plasma (FFP) on preventing IVH - did not indicate any specific type of FFP that was used. Due to the heterogeneity of such studies, it is indeed recommended to specify this point in future research. Although one small study [3] reported reduced IVH with volume expansion, this was not supported by any other later study [5,6]. The role of early FFP application after coagulation screening for IVH prevention was reported recently by Dani et al. [4], as discussed in our manuscript. Notably, additional references from the 1990’s [5-8] mentioned by the author might strengthen our conclusions but did not add any new findings, and thus were not quoted within our narrative review. Naturally, as we focused upon hematological interventions, not all other pharmacological agents [9,10] were discussed in detail. In summary, the aim of our publication was to promote the issue of potential IVH prevention by coagulation manipulation. We are happy that this goal has been achieved as increased awareness to the topic is manifested by addressing this rebuttal. We appreciate Dr Al-Abdi’s enligh tening remarks and contribution.
Address for correspondence: Prof. Gili Kenet, Thrombosis unit, National Hemophilia Center & Sheba Medical Center, Tel Hashomer, Israel. E-mail: [email protected]
R eferences 1. Kuperman AA, Brenner B, Kenet G. Intraventricular haemorrhage in preterm infants - can we improve outcome by addressing coagulation? J Matern Fetal Neonatal Med 2013 Aug 23. [Epub ahead of print]. 2. Al-Abdi SY. Virus-inactivated plasma and intraventricular hemor rhage in preterm neonates. J Matern Fetal Neonatal Med 2013; [Epub ahead of print]. 3. Beverley DW, Pitts-Tucker TJ, Congdon PJ, et al. Prevention of intraventricular haemorrhage by fresh frozen plasma. Arch Dis Child 1985;60:710-3. 4. Dani C, Poggi C, Ceciarini F, et al. Coagulopathy screening and early plasma treatment for the prevention of intraventricular hem orrhage in preterm infants. Transfusion 2009;49:2637^44. 5. Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Lancet 1996;348:229-32. 6. The Northern Neonatal Nursing Initiative [NNNI] Trial Group. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. Eur J Pediatr 1996;155:580-8. 7. Ekblad H, Kero P, Shaffer SG, Korvenranta H. Extracellular volume in preterm infants: influence of gestational age and colloids. Early Hum Dev 1991;27:1-7. 8. Ekblad H, Kero P, Korvenranta H. Renal function in preterm infants during the first five days of life: influence of maturation and early colloid treatment. Biol Neonate 1992;61:308-17. 9. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010;(7):CD000174. 10. Cools F, Offringa M. Neuromuscular paralysis for newborn infants receiving mechanical ventilation. Cochrane Database Syst Rev. 2005;(2):CD002773.
Copyright of Journal of Maternal-Fetal & Neonatal Medicine is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
